Andexanet Alfa (Andexxa): Reversing the Factor Xa Inhibitors

Part of the ICU Emergencies Hub — browse every related guide in one place.

Updated July 2026  |  More ICU nursing guides →

Apixaban and rivaroxaban are everywhere — atrial fibrillation, DVT, PE — and for years the honest answer to "how do we reverse them?" was "we mostly can't." Andexanet alfa changed that conversation. It is a specific reversal agent for factor Xa inhibitors, and while it is more complicated to give than a simple two-vial push, understanding its logic keeps the ICU nurse a step ahead when a patient on Eliquis or Xarelto is bleeding into their brain.

How it works — the decoy receptor

Factor Xa inhibitors (apixaban/Eliquis, rivaroxaban/Xarelto, and the parenteral indirect inhibitors) work by binding and blocking factor Xa, the enzyme that converts prothrombin to thrombin. Andexanet alfa is a modified, catalytically inactive version of factor Xa. It acts as a decoy: it binds the circulating Xa-inhibitor molecules with high affinity, sequestering them away from the patient's real factor Xa. With the inhibitor mopped up, native factor Xa is freed to drive clotting again.

Because the decoy is inactive, it doesn't itself generate thrombin — but the net effect of freeing native Xa is a return of coagulation. That restored coagulation is also the source of andexanet's central safety concern, which we'll get to.

When it's indicated

Andexanet alfa is used for life-threatening or uncontrolled bleeding in patients taking a factor Xa inhibitor — most prominently intracranial hemorrhage, but also other major bleeds. Its role around urgent surgery is more limited and less established than idarucizumab's is for dabigatran. As with all these agents, it is not for a supratherapeutic lab value without bleeding, and it does nothing for dabigatran, warfarin, or heparin.

The dosing logic: bolus then infusion

This is where andexanet differs most from the other reversal agents. It is given as an IV bolus followed by a continuous IV infusion, because the Xa inhibitor is still circulating and would otherwise re-inhibit factor Xa as soon as the bolus wears off. The infusion holds the reversal in place for a couple of hours.

There are two regimens — commonly called low dose and high dose — and which one a patient gets depends on which Xa inhibitor they took, how much, and how long ago the last dose was:

The practical nursing takeaway: andexanet is not a fixed "give X grams" order. Expect a bolus at a set rate followed by an infusion, and expect pharmacy to have calculated the regimen from the drug/dose/timing. Your job is accurate administration of both phases and knowing that stopping the infusion early can let anticoagulation creep back.

The heparin caution — a real trap

Here is a point that catches teams off guard: because andexanet alfa binds and inactivates factor Xa inhibitors, it also interferes with heparin's anticoagulant activity (heparin works through antithrombin to inhibit factor Xa). A patient who has recently received andexanet may be unresponsive to heparin — which matters enormously if that patient then needs to go on cardiopulmonary bypass or otherwise needs heparin anticoagulation. Andexanet has not been validated as reliable in the setting where heparin anticoagulation is required, and heparin resistance after andexanet is a documented concern. If a bleeding, Xa-inhibited patient might imminently need bypass, the whole reversal plan has to account for this.

The thrombotic risk

The flip side of restoring coagulation in someone whose baseline is a prothrombotic condition is thrombosis. Andexanet carries a boxed warning for thromboembolic events, ischemic events, cardiac arrest, and sudden death. These patients are on a factor Xa inhibitor for a reason — afib, prior clot, mechanical issue — and reversing them removes their protection. After administration, the team watches for new stroke, MI, DVT, PE, and other thrombotic events, and re-anticoagulation is resumed as soon as it is medically safe. As the ICU nurse, you're monitoring neuro status, limb perfusion, chest pain, and any sign that a clot has formed while the anticoagulant was neutralized.

Andexanet vs. 4-factor PCC

Many institutions still use 4-factor PCC (Kcentra) off-label for factor Xa inhibitor bleeding — it's fast, familiar, cheaper, and doesn't cause the heparin-resistance problem. Andexanet is the drug specifically designed and studied for this indication. The choice between them is institution- and case-specific and is made by the team; it often hinges on availability, cost, the specific bleed, and whether the patient might need heparin soon. You don't make that call, but knowing both are on the table helps you understand the order you receive.

The nursing bottom line

Andexanet alfa is the targeted reversal for factor Xa inhibitors — apixaban and rivaroxaban — and it works by acting as a decoy that soaks up the drug. It's given as a bolus followed by an infusion, with the regimen (low vs. high dose) chosen from which drug, how much, and how recently it was taken. Two cautions define the bedside picture: it can render the patient resistant to heparin, which is critical if bypass is coming, and it carries a boxed warning for thrombotic events because you've removed the patient's anticoagulation. Confirm the drug is truly an Xa inhibitor, administer both phases faithfully, and watch hard for new clots afterward.

Related: idarucizumab (Praxbind) for dabigatran reversal, 4-factor PCC (Kcentra) for warfarin reversal, and anticoagulation reversal in intracranial hemorrhage.